Healthcare Professionals
React 68 Catheter
Aspiration Catheter for
Acute Ischemic Stroke
Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
Healthcare Professionals
React 68 Catheter
Aspiration Catheter for
Acute Ischemic Stroke
The React™ 68 Catheter features a coil and braid design along with end-to-end Nitinol construction — easing navigation to the M1 and M2 segments. This catheter combined with the Riptide™ Aspiration System is designed to revascularize patients experiencing acute ischemic stroke.
At Medtronic, we’re constantly innovating to expand options for treatment in the fight against acute ischemic stroke (AIS). We provide solutions like the React 68 Catheter to empower the expertise of our physician partners, and enable them to treat their AIS patients.
Discover the React™ 68 Catheter was built to help treat Acute Ischemic Stroke patients with speed, agility, and confidence by watching its durable, end-to-end flat Nitonol construction and combined COil + BRAid design in action.
More information (see more)Less information (see less)
Navigability of a Coil
Pushability of a Braid
Durability of Nitinol
React™ COBRA Technology
Overlapping combination of a Nitinol COil+ BRAid to deliver flexibility and pushability.
React 68 Catheter Instructions for Use
This technical manual includes indications, warnings, precautions, product specifications, instructions, and clinical study summary. Find in the product labeling supplied with each device or call Medtronic at 800-961-9055.
Download the model specifications sheet to use as a quick reference guide for the React 68 Catheter and the Riptide Aspiration System.
The Riptide Aspiration System is intended for use in the revascularization of patients with acute ischemic stroke secondary to intracranial large vessel occlusive disease (within the internal carotid, middle cerebral M1 and M2 segments, basilar, and vertebral arteries) within 8 hours of symptom onset. Patients who are ineligible for intravenous tissue plasminogen activator (IV t-PA) or who fail IV t-PA therapy are candidates for treatment.
All claims have been substantiated and data is on file TR-NV15399 Rev A.